Utilization of dialkylfumarates

Details Utilization of dialkylfumarates Utilization of dialkylfumarates

2007-06-20

2009-11-17

Weddington, Kevin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S903000, C514S960000

Reexamination Certificate

active

07619001

ABSTRACT:
The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

REFERENCES:
patent: 3832287 (1974-08-01), Gale et al.
patent: 4515974 (1985-05-01), Zecher et al.
patent: 4746668 (1988-05-01), Sato et al.
patent: 4851439 (1989-07-01), Speiser et al.
patent: 4959389 (1990-09-01), Speiser et al.
patent: 5149695 (1992-09-01), Speiser et al.
patent: 5214196 (1993-05-01), Blank
patent: 5242905 (1993-09-01), Blank
patent: 5359128 (1994-10-01), Blank
patent: 5424332 (1995-06-01), Speiser et al.
patent: 5451667 (1995-09-01), Speiser et al.
patent: 5538968 (1996-07-01), Chiesi et al.
patent: 5548059 (1996-08-01), Bayley et al.
patent: 5589504 (1996-12-01), Dannenburg et al.
patent: 5972363 (1999-10-01), Clikeman et al.
patent: 6277882 (2001-08-01), Joshi et al.
patent: 6355676 (2002-03-01), Joshi et al.
patent: 6359003 (2002-03-01), Joshi et al.
patent: 6436992 (2002-08-01), Joshi et al.
patent: 6509376 (2003-01-01), Joshi et al.
patent: 2003/0013761 (2003-01-01), Joshi et al.
patent: 2004/0054001 (2004-03-01), Joshi et al.
patent: 2006/0069161 (2006-03-01), Lee et al.
patent: 2007/0248662 (2007-10-01), Joshi et al.
patent: 2008/0233185 (2008-09-01), Joshi et al.
patent: 2248955 (2001-08-01), None
patent: 1125141 (1996-06-01), None
patent: 25 30 372 (1977-01-01), None
patent: 26 21 214 (1977-11-01), None
patent: 35 31597 (1987-03-01), None
patent: 38 34794 (1990-04-01), None
patent: 19721099 (1998-11-01), None
patent: 0 188749 (1986-07-01), None
patent: 0 312697 (1989-04-01), None
patent: 0 518388 (1992-12-01), None
patent: 0 793966 (1997-09-01), None
patent: 1 216699 (1970-12-01), None
patent: 1 422726 (1976-01-01), None
patent: 2 291422 (1996-01-01), None
patent: WO 89/01930 (1989-03-01), None
patent: WO 94/28883 (1994-12-01), None
patent: WO 95/25102 (1995-09-01), None
patent: WO 96/01122 (1996-01-01), None
patent: WO 96/02244 (1996-02-01), None
patent: WO 96/27369 (1996-09-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 98/04290 (1998-02-01), None
patent: WO 98/27970 (1998-07-01), None
patent: WO 98/52549 (1998-11-01), None
patent: WO 99/21565 (1999-05-01), None
patent: WO 01/59072 (2001-08-01), None
patent: WO 02/02190 (2002-01-01), None
patent: WO 03/032969 (2003-04-01), None
patent: WO 2004/096216 (2004-11-01), None
patent: WO 2005/027899 (2005-03-01), None
patent: WO 2005/044272 (2005-05-01), None
patent: WO 2006/037342 (2006-04-01), None
patent: WO 2006/050730 (2006-05-01), None
patent: WO 2006/055871 (2006-05-01), None
Andersson et al., “Cytokine profile in interferon-β treated multiple sclerosis patients: reduction of interleukin-10 mRNA expressing cells in peripheral blood,” Eur. J. Neurol. 4: 567-571, 1997.
Becanovic et al., “Paradoxical effects or arthritis-regulating chromosome 4 regions on myelin oligodendrocyte glycoprotein-induced encephalomyelitis in congenic rats,” Eur. J. lmmunol. 33: 1907-1916, 2003.
Correale et al., “Sulfasalazine aggravates experimental autoimmune encephalomyelitis and causes an increase in the number of autoreactive T cells,” J. Neuroimmunol. 34:109-120, 1991.
Dahlman et al., “Quantitative trait loci disposing for both experimental arthritis and encephalomyelitis in the DA rat; impact on severity of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis and antibody isotype pattern,” Eur. J. Immunol. 28:2188-2196, 1998.
De Graaf et al., “MHC Class 11 Isotype- and Allele-Specific Attenuation of Experimental Autoimmune Encephalomyelitis,” J. Immunol., 173: 2792-2802, 2004.
Di Marco et al., “Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis,” J. Neuroimmunol. 116: 168-177, 2001.
Djerbi et al., “Expression of the Long Form of Human FLIP by Retroviral Gene Transfer of Hemopoietic Stem Cells Exacerbates Experimental Autoimmune Encephalomyelitis,” J. Immunol. 170: 2064-2073, 2003.
Gielen et al., “Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems,” J. Neuroimmunol., 164: 93-104, 2005.
Guggenmos et al., “Antibody Cross-Reactivity between Myelin Oligodendrocyte Glycoprotein and the Milk Protein Butyrophilin in Multiple Sclerosis,” J. Immunol. 172: 661-668, 2004.
Issazadeh et al., “Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β,” J. Neuroimmunol. 61: 205-212, 1995.
Issazadeh et al., “Interferon γ, Interleukin 4 and Transforming Growth Factor β in Experimental Autoimmune Encephalomyelitis in Lewis Rats: Dynamics of Cellular mRNA Expression in the Central Nervous System and Lymphoid Cells,” J. Neurosci. Res. 40: 579-590, 1995.
Issazadeh et al., “Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β,” J. Neuroimmunol. 69: 103-115, 1996.
Issazadeh et al., “Major histocompatibility complex-controlled protective influences on experimental autoimmune encephalomyelitis are peptide specific,” Eur. J. lmmunol. 27: 1584-1587, 1997.
Khademi et al., “Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis,” J. Neuroimmunol. 103:202-210, 2000.
Khademi et al., “T Cell lg- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis,” J. Immunol. 172: 7169-7176, 2004.
Khademi et al., “Induction of systemic TNFα Expression in Natalizumab-treated multiple sclerosis,” Eur. J. Neurol., 15: 309-12, 2008.
Kjellén et al., “Genetic influence on disease course and cytokine response in relapsing experimental allergic encephalomyelitis,” Int. Immunol. 10: 333-340, 1998.
Krakauer et al., “Dynamic T-lymphocyte Chemokine Receptor Expression Induced by Interferon-beta Therapy in Multiple Sclerosis,” Scand. J. Immunol. 64: 155-163, 2006.
Link et al., “Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis,” J. Neuroimmunol. 38: 63-73, 1992.
Link et al., “Organ-specific Autoantigens Induce Transforming Growth Factor-β mRNA Expression in Mononuclear Cells in Multiple Sclerosis and Myasthenia Gravis,” Annals Neurol. 35: 197-203, 1994.
Link et al., “Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis,” Neurology 44: 728-734, 1994.
Link et al., “Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-γ, interleukin-4 and transforming growth factor-β,” J. Neuroimmunol. 49:9-18, 1994.
Link et al., “Increased Transforming Growth Factor-β, Interleukin-4, and Interferon-γ in Multiple Sclerosis,” Ann. Neurol. 36: 379-386, 1994.
Lobell et al., “Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis,” J. Exp. Med. 187: 1543-1548, 1998.
Lobell et al., “

Affiliated with

Also associated with

Rating

Utilization of dialkylfumarates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Utilization of dialkylfumarates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Utilization of dialkylfumarates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4063946